home About Us People Portfolio News Contact Us Fund I Investor Login » Fund II Investor Login » Fund III Investor Login »


Tag: 2018

Feb20Dynavax Secures $175 Million in Non-Dilutive Debt Financing »

-- Proceeds to be Used to Commercialize HEPLISAV-B™ [Hepatitis B Vaccine (Recombinant), Adjuvanted] in United States and Advance Company's Immuno-Oncology Product Candidates --   -- Company Deploying HEPLISAV-B...

Read More »

Feb12Viveve Announces Closing of Public Offering of Shares of Common Stock »

Englewood, CO -- (Marketwired) -- 02/12/18 -- Viveve Medical, Inc. ("Viveve") (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced the closing of its previously...

Read More »

Feb9Tandem Diabetes Care Announces Pricing of $60 Million Underwritten Public Offering of Common Stock »

San Diego --(BUSINESS WIRE) --Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today...

Read More »

Jan25Synergy Pharmaceuticals Announces FDA Approval of TRULANCE® (Plecanatide) for the Treatment of Irritable Bowel Syndrome with Constipation (IBSC) in Adults »

NEW YORK- (BUSINESS WIRE)-- Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) announced today that the U.S. Food and Drug Administration (FDA) has approved TRULANCE ®(plecanatide) 3 mg tablet for the...

Read More »

Jan25Strongbridge Biopharma plc Announces Pricing of Public Offering of Ordinary Shares »

Dublin, Ireland and Trevose, Pa., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ:SBBP) (the “Company”) today announced that it has priced its...

Read More »

Jan17Strongbridge Biopharma plc Announces Acquisition of the U.S. and Canadian Rights to MACRILEN™ (macimorelin) from Aeterna Zentaris »

-- MACRILEN is the First and Only FDA-Approved Oral Drug Indicated For the Diagnosis of Adult Growth Hormone Deficiency, a Rare Endocrine Disorder -- -- MACRILEN is Strongbridge...

Read More »